No Data
No Data
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?
Leerink Partners Maintains Turnstone Biologics(TSBX.US) With Hold Rating, Maintains Target Price $1
Piper Sandler Downgrades Turnstone Biologics to Neutral From Overweight, Adjusts Price Target to $0.40 From $3.75
Sector Update: Health Care Stocks Decline Late Afternoon
Express News | Turnstone Biologics Shares Are Trading Higher After Announcing the Discontinuation of Its Studies Evaluating TIDAL-01 and Will Explore Strategic Alternatives. Additionally, the Company Will Reduce Its Workforce and Implement Cost-containment and...
Turnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives Review